Atopic Dermatitis Market 2024 - Trend Analysis, Industry Growth, Key Players, Growth Opportunities And Outlook By 2033

The atopic dermatitis market size has grown rapidly in recent years. It will grow from $7.51 billion in 2023 to $8.7 billion in 2024 at a compound annual growth rate (CAGR) of 15.9%. The growth in the historic period can be attributed to medical understanding and awareness, incidence and prevalence rates, patient advocacy and support, treatment options evolution, research and development.

The atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $15.27 billion in 2028 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to biologic therapies advancements, immunomodulators and small molecule drugs, pediatric-specific treatments, gene therapy and precision medicine, digital health integration. Major trends in the forecast period include technological advancements in topicals, pediatric ad care focus, environmental and allergen management, precision diagnosis tools.

Market Overview -
Atopic dermatitis is a dermatological condition that causes dryness and itching of the skin. It is a chronic condition that progresses over time and is not spread by contact.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=8285&type=smp

Rising Prevalence Of Atopic Dermatitis Is A Key Catalyst For The Growth Of The Atopic Dermatitis Market
The high prevalence of atopic dermatitis is expected to propel the growth of the atopic dermatitis market forward. Atopic dermatitis, also called eczema, is a skin condition that causes dryness and itchiness of the skin. The increasing prevalence of atopic dermatitis increases the need for diagnosis and treatment of the disease. For instance, according to the National Eczema Association, a US-based organization working to spread awareness related to eczema, in 2021, 31.6 million people in the US had some form of eczema, which was about 10% of the total population. Approximately 9.6 million children under the age of 18 had atopic dermatitis, and 80% of the individuals were affected by dermatitis before the age of 6 years. Therefore, the increasing prevalence of atopic dermatitis is driving the growth of the atopic dermatitis market.

Competitive Landscape -
Major companies operating in the atopic dermatitis market report are Sanofi SA, Meda AB, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, F Hoffmann-La Roche AG, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Mylan MV, Allergan plc, Encore Dermatology Inc., Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Roche Holding AG, Valeant Pharmaceuticals International Inc., Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eisai Co. Ltd., Gilead Sciences Inc., Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited

Product Innovations Transforms The Atopic Dermatitis Market
Product innovations are a key trend gaining popularity in the atopic dermatitis market. Major companies in the market are introducing innovative products to strengthen their market position. For instance, in June 2022, Regeneron Pharmaceuticals Inc. a US-based biotechnology company received FDA approval for Dupixent (dupilumab). Dupixent is used for children with moderate-to-severe atopic dermatitis, ages 6 months to 5 years. Topical corticosteroids can be used with or without dupixent. Dupixent functions by inhibiting the signaling of two major Type 2 inflammatory sources (IL-4 and IL-13), which are crucial in the development of eosinophilic esophagitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and asthma .

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

Key Segments -
The atopic dermatitis market covered in this report is segmented -
1) By Drug Class: Corticosteroids, Emollients/Moisturizers, IL-4 and PDE4 Inhibitors, Calcineurin Inhibitors, Antibiotics, Other Drug Classes
2) By Mode of Administration: Topical, Injectable, Oral
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.